Page last updated: 2024-11-02

pifithrin and DiGeorge Syndrome

pifithrin has been researched along with DiGeorge Syndrome in 1 studies

pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source

DiGeorge Syndrome: Congenital syndrome characterized by a wide spectrum of characteristics including the absence of the THYMUS and PARATHYROID GLANDS resulting in T-cell immunodeficiency, HYPOCALCEMIA, defects in the outflow tract of the heart, and craniofacial anomalies.

Research Excerpts

ExcerptRelevanceReference
" Half dosage of this gene in humans causes most of the features of the DiGeorge or Velocardiofacial syndrome phenotypes, including aortic arch and cardiac outflow tract abnormalities."1.40p53 Suppression partially rescues the mutant phenotype in mouse models of DiGeorge syndrome. ( Baldini, A; Caprio, C, 2014)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Caprio, C1
Baldini, A1

Other Studies

1 other study available for pifithrin and DiGeorge Syndrome

ArticleYear
p53 Suppression partially rescues the mutant phenotype in mouse models of DiGeorge syndrome.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Sep-16, Volume: 111, Issue:37

    Topics: Animals; Arteries; Benzothiazoles; Branchial Region; Chromatin; Crosses, Genetic; DiGeorge Syndrome;

2014